Загрузка...

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis

The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were dev...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Rheumatology (Oxford)
Главные авторы: Avci, Ali Berkant, Feist, Eugen, Burmester, Gerd Rüdiger
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2021
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8098113/
https://ncbi.nlm.nih.gov/pubmed/33950228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa893
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!